Guest post: K2VITAL® Vitamin K2 MK-7: On the Tipping Point for Explosive Growth

June 7, 2017

Explosive Market Potential by Consumer

Vitamin K2 MK-7 has been marketed to seniors in the context of bone and heart disease. This ‘glass-half-empty’ positioning sells short the potential of this essential vitamin. K2 is needed throughout life to achieve full health potential – from children to mothers, athletes to seniors. It is critical during the rapid bone growth phase from childhood to adolescence, to build optimal Bone Mineral Density (BMD) before the onset of menopause, and to grow and maintain bone into senior years (yes, bones grow in response to both K2 and resistance training all through life).

Existing Products and Categories are Tailor-made for K2 Extension and Upgrade

Products and market categories that target bone or heart health provide natural opportunities for K2 product extension or upgrade – introducing a fresh marketing narrative firmly rooted in science. Beyond the well established bone and heart health categories, there is significant potential for innovation in the multivitamin, cardiovascular, women’s health, healthy ageing
and sports nutrition market categories. K2 is also a perfect fit for the children’s category, for example in gummy format. In fact, any product that contains calcium or D3 is a candidate for K2 inclusion.

The K2 Stability Problem Offers Opportunity and Competitive Advantage

K2 is a fat-soluble vitamin and like all others it can degrade in certain formulations and environments. Unprotected K2 is particularly susceptible to degradation in combination with calcium or magnesium salts. A recent market study published by Kappa Bioscience showed that only 2 of 39 K2 plus calcium or magnesium products met label claim, and half failed to meet label claim by 50% or more.
The inherently poor stability characteristics of unprotected K2 is problematic because calcium and magnesium are central to many bone and heart health formulations. To date this problem has limited the use of K2 in these market categories, as well as extension categories where calcium or magnesium salts are present such as multivitamins.
Protected, microencapsulated K2VITAL® DELTA, has been proven stable when formulated with calcium and magnesium salts. The proprietary dual layer K2VITAL® DELTA beadlet protects the K2, achieving excellent stability with minimal overage. In fact, K2VITAL® DELTA is the only form of K2 with proven stability, backed by years of empirical stability data that is suitable for formulation with calcium or magnesium salts.

K2VITAL® DELTA Stands Alone, but Product Testing is the Key to Market Education

In 1948 it was recognised that vitamin D was unstable in the presence of calcium salts. The K2 market has been slower to act upon the science of K2 stability – as the results of the recent Kappa Market Study clearly demonstrate. Though K2VITAL®DELTA should stand peerless on the playing field, brands still knowingly and unknowingly launch K2 products that will fall
short on promises to consumers.
Market education is the key to products that deliver brand value, and product testing is the key to market education.

K2VITAL® for Bones

Calcium relies on vitamin K2 MK-7 and vitamin D3 to regulate optimal calcium function in the body. Vitamin D3 aids calcium absorption into the bloodstream where it can be put to work. K2 activates osteocalcin proteins that integrate calcium into bone. Throughout all stages of life, healthy bones are dependent on sufficient K2 intake – something rarely achieved in the western diet.

K2VITAL® for Heart

K2 activates matrix Gla proteins (MGP) which bind excess calcium in blood to prevent deposit in vessels and arteries. K2 can even reverse existing calcification and reduce arterial stiffness.

Author: Kappa Bioscience

Pathway International is the exclusive distributor for Kappa Bioscience in Australia and New Zealand.

For more information please contact us on
Phone: 02 9984 2700

Read More

CEO of Vitex Pharmaceuticals, Dr Aniss Chami is proud to be appointed as a career ambassador for Careers NSW.
Read More >
Dr Aniss Chami, Chief Executive Officer of Vitex Pharmaceuticals interviewed by the Western Sydney Leadership Dialogue
Read More >
Vitex to Expand Into the Aerotropolis
Read More >
Vitex CEO Dr Aniss Chami Appointed Board Director of CHP Australia
Read More >
Vitex Pharmaceuticals’ Chief Executive Officer, Dr Aniss Chami, a panel discussion with Blacktown City Council.
Vitex CEO Dr Aniss Chami Joins A Panel Discussion with Blacktown City Council
Read More >
Vitex Pharmaceuticals’ Chief Procurement Officer, Lucie Chami, discusses the impact of Coronavirus on procurement via Podcast on Chartered Institute of Procurement and Supply
Vitex CPO Lucie Chami Discusses the Impact of Coronavirus
Read More >
Vitex Pharmaceuticals’ CEO, Dr Aniss Chami had the pleasure of hosting over forty foreign diplomats based in NSW. The Western Sydney Investment Attraction Office, on behalf of the Department of Foreign Affairs and Trade, organised a visit to Western Sydney to showcase investment and trade opportunities in this rapidly expanding region.
Vitex CEO Dr Aniss Chami Welcomes NSW Diplomats at Vitex Pharmaceuticals
Read More >
Vitex Pharmaceuticals Chief Executive Officer, Dr Aniss Chami, has been awarded the 2019 Corporate Citizen of the Year award by Blacktown City C
Vitex CEO Dr Aniss Chami Wins Corporate Citizen of the Year 2019 Award
Read More >
Vitex Pharmaceuticals’ CEO, Dr Aniss Chami joined the Western City & Aerotropolis Authority Industry Symposium that took place on Monday 16 December 2019 at Warwick Farm.
Vitex CEO Dr Aniss Chami Participates at the Western City & Aerotropolis Authority Industry Symposium
Read More >